Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has appointed Laboratoires Plasto Santé to manufacture its first drug delivery patches.
The first batch of patches, based on Medherant’s proprietary TEPI Patch technology, will be used for clinical studies of the company’s revolutionary ibuprofen patches. The new studies, designed to test safety and efficacy, are planned to start in the autumn of 2017.
Nigel Davis, CEO of Medherant, said: “We’re delighted to have Laboratoires Plasto Santé as our contract manufacturer at this exciting time in our company’s growth. Combining our TEPI Patch technology with Laboratoires Plasto Santé’s product manufacturing expertise will enable us to start clinical trials and facilitate rapid growth of our library of patch-delivered drugs.”
Bruno Loiseau, Managing Director of Laboratoires Plasto Santé, said: “We’re looking forward to working with Medherant as it progresses its patches towards the market.”
“We are expanding our patch production capacity and will support Medherant with our expertise in transdermal delivery systems as they bring TEPI Patch ibuprofen to market and begin clinical studies with other products.”